Cannabis Is Here. The Public Health Work Is Just Beginning.

Cannabis did not quietly arrive. It moved from the margins into everyday life with speed and scale. It now touches healthcare visits, workplace safety, insurance claims, disability evaluations, and conversations about fairness and enforcement. Whether someone supports legalization is no longer the defining issue. Cannabis is here. The real question is whether we are managing its impact with the same seriousness we apply to other widespread health exposures.

Public health gives us a way to approach this without getting stuck in opinion. Public health is not about telling people what to do. It is about managing risk across populations. It is the same discipline used to reduce drunk driving, lower smoking rates, and respond to the opioid crisis. The work follows a familiar pattern. First understand what is happening. Then design responses that shape outcomes. Finally build systems that ensure protections actually work. When we apply this structure to cannabis, the conversation shifts from debate to accountability.

Start with assessment. Some trends are clear across states and studies. Adult use increases when access expands. Cannabis use disorder rises in measurable ways. Emergency department visits linked to cannabis exposure increase as well. These are not moral judgments. They are signals that systems are absorbing new pressures. Hospitals, clinicians, and emergency services feel those pressures whether they are prepared or not.

Assessment is further complicated by the fact that the stigma and the science surrounding cannabis are still thick with bias and shaped by decades of inconsistent research standards. Historical prohibition limited rigorous study, while modern research often struggles with small sample sizes, poorly defined exposure variables, and methods that fail to reflect real world use. Studies frequently group vastly different products and patterns together, producing conclusions that are either overstated or inconclusive. The result is a body of evidence that can be misinterpreted in multiple directions, reinforcing opinion rather than clarifying risk. Recognizing these limitations is not an argument against science. It is a reminder that better methods are essential if we want clearer answers.

At the same time, we are trying to understand this landscape with incomplete tools. Cannabis is not one product. It is a rapidly evolving category with wide variation in potency, formulation, and route of use. A person using a high potency concentrate is not experiencing the same exposure as someone taking a low dose edible, yet research often treats them as comparable. Product innovation has moved faster than our ability to measure it. We often lack basic data such as dose, frequency, or product type when evaluating outcomes. That makes it harder to draw precise conclusions and easier to miss emerging problems.

This creates a core challenge. Cannabis may be legal in many places, but the infrastructure to monitor its effects is still catching up. Public health systems do not consistently track potency trends or connect specific products to adverse events. Without that visibility, decision makers are navigating without a full dashboard. You cannot manage what you do not measure. Currently, we are up against incomplete education and regulations that promote the interests of legislation and business interests over the public health of the medical cannabis community.

It is also critical to recognize that recreational cannabis use is not the same as medical use. Medical use, at its best, offers some level of structure, guidance, and clinical context. Recreational markets often do not. Many consumers are left to navigate a sea of misinformation designed to promote sales, increase use, and sometimes even encourage misuse. Without credible guidance, individuals are asked to make complex health decisions on their own, which is not how we manage other substances with real physiologic effects.

The next step is design. Legalization is not a single event. It is a series of choices about how a market functions. Decisions about taxation, retail density, marketing, and product strength all shape behavior. Different choices produce different outcomes. One of the clearest drivers of risk is potency. High THC products concentrate effects and increase the likelihood of adverse reactions, especially among new or vulnerable users. We have seen similar patterns before with high proof alcohol. Stronger products require clearer education and thoughtful guardrails if the goal is to reduce harm.

Markets also behave predictably. Companies compete. They innovate. They develop products that act faster or feel stronger because that is what markets reward. This is not a conspiracy. It is basic economics. But it means public education and health messaging must work harder to keep pace so that consumers understand what they are using.

The third function is assurance. Do we have systems in place to catch problems early and respond? In many cases the answer is not yet. Healthcare providers often receive little training about cannabis, which leads to inconsistent screening and documentation. The Association of Cannabinoid Specialists offers various courses and educational sessions to educate those providing care to medical cannabis patients.

Adverse events are underreported, so warning signals can remain scattered instead of forming a clear picture. Product labeling varies widely, leaving individuals to interpret dosing and risk on their own. We would not expect patients to interpret complex medications without guidance, yet that is often what happens here.

Equity adds another layer that cannot be ignored. The risks and benefits associated with cannabis do not fall evenly across communities. Access to reliable information, clinical support, and economic opportunity differs by geography and income. Some groups experience greater exposure to harm while others experience more of the benefits. Saying we want fairness is not enough. Equity requires measurement. We must look at who is affected, where outcomes differ, and whether systems respond when disparities appear.

Designing with equity in mind means building surveillance that can detect differences early, adjusting strategies when harm concentrates, and aligning healthcare access with real patterns of use. Access alone does not create fairness. Support, education, and prevention matter just as much.

The larger lesson is straightforward. Cannabis, like alcohol or tobacco, sits at the intersection of personal choice and collective responsibility. Public health does not seek to eliminate use. It seeks to reduce preventable harm, improve understanding, and ensure systems respond to evidence rather than assumptions.

The question in front of us is no longer whether cannabis should exist. That decision has already been made by society. The question now is whether we are willing to manage it with intention. Competence in this space does not mean overreaction or neglect. It means building the measurement, education, and health infrastructure that matches the scale of exposure.

Cannabis is not just a cultural shift or a commercial story. It is a public health reality unfolding in real time. How we respond will determine whether the long term outcome reflects preventable harm or informed adaptation.

Learn more about Association of Cannabinoid Specialists' Board member, Alicia Schaal, MS, RN, BSN, PHN here!